Expand BIOA Menu
BIOA MENU

BIOA Latest Press Releases

-- June 16, 2026 --

BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk Globe Newswire 8:00 AM

-- May 22, 2026 --

BioAge Labs to Present at Upcoming Investor Conferences Globe Newswire 9:00 AM

-- May 8, 2026 --

BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates Globe Newswire 9:00 AM

-- May 4, 2026 --

BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026 Globe Newswire 4:30 PM

-- April 21, 2026 --

BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP Globe Newswire 7:00 AM

-- April 13, 2026 --

BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference Globe Newswire 4:30 PM

-- March 24, 2026 --

BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025 Globe Newswire 9:00 AM

-- March 23, 2026 --

New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD congress PRNewswire 3:50 AM

-- February 19, 2026 --

BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference Globe Newswire 4:30 PM

-- January 21, 2026 --

BioAge Announces Pricing of Upsized $115.0 Million Public Offering Globe Newswire 10:30 PM

-- January 20, 2026 --

BioAge Announces Proposed Public Offering Globe Newswire 4:01 PM
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026 Globe Newswire 9:00 AM
Market Data Delayed 15 Minutes